HPB is taking Cylert (pemoline) off the market in Canada

HPB is taking Cylert (pemoline) off the market in Canada.

They say the risk of severe liver toxicity outweighs the benefits of using Cylert for Attention Deficit Hyperactivity Disorder (ADHD). Liver failure from Cylert can result in transplants and even death.

Patients who really need Cylert can still get it through Health Canada's Special Access Program.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter Canada includes:

  • 12 issues every year, with brief articles about new meds and hot topics
  • 300+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get quote